Alpha-1,3-mannosyltransferase (ALG3) is an enzyme located in the endoplasmic reticulum membrane, where it plays an essential role in protein N-glycosylation by transferring the sixth of nine mannose residues from dolichol-phosphate mannose to the lipid-linked oligosaccharide precursor. This step is crucial for the correct assembly of the dolichol-linked oligosaccharide, which is later transferred en bloc to nascent proteins. Mutations in the ALG3 gene cause congenital disorder of glycosylation type Id (ALG3-CDG), an autosomal recessive multisystem disorder marked by neurodevelopmental delay, dysmorphic features, visual impairment, and currently without specific treatment. Diagnosis can be supported by specific glycoform and oligosaccharide biomarker patterns, but is confirmed genetically[1][2][3].
Other names
Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferaseDol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferaseAsparagine-linked glycosylation protein 3 homologNot56-like proteinNOT56LNot56CDGS4D16Ertd36eCarbohydrate deficient glycoprotein syndrome type IVDolichyl-phosphate-mannose--glycolipid alpha-mannosyltransferaseCDG1DCDGS6NOTnotMannosyltransferase 6 deficiencyAsparagine-linked glycosylation 3 homolog (S. cerevisiae, alpha-1,3-mannosyltransferase)EC 2.4.1.258EC 2.4.1.130
02
Biological functions
N-linked protein glycosylationTransfer of mannose residues to growing oligosaccharide chainsAssembly of lipid-linked oligosaccharide precursors in the endoplasmic reticulumPrecursor formation for protein N-glycosylation
03
Disease associations
Inherited metabolic disorder (congenital disorder of glycosylation, specifically CDG type Id/ALG3-CDG)Neurological diseaseCongenital malformation syndromesVisual/ophthalmological disorders
04
Safety considerations
No approved therapies; main challenge is multisystemic phenotype with severe neurodevelopmental impairment and failure to thriveDiagnostic challenge as symptoms may overlap with other congenital glycosylation disorders
05
Biomarkers
Serum and fibroblast levels of Man0-4GlcNAc2 (elevated in ALG3 deficiency)Transferrin glycoform analysis (type 1 pattern by isoelectric focusing/mass spec)
Beyond the preview
Go deeper on Alpha-1,3-mannosyltransferase (ALG3) (ALG3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha-1,3-mannosyltransferase (ALG3) (ALG3).